Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Blickensderfer

Nurse Practitioner Bowling Green, OH Nurse Practitioner

NPI 1528145026 CMS profile 10958802

1215 Ridgewood Dr, Suite B, Bowling Green, OH 43402

Open in the dashboard

General payments

$3,212

187 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Blickensderfer of Bowling Green, OH is reported in the CMS Open Payments database as having received $3,212 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $686 32
2024 General $889 50
2023 General $533 33
2022 General $479 34
2021 General $625 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Blickensderfer
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kelly Blickensderfer were reported at $686. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kelly Blickensderfer Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $625 $135 $40–$426 $132
2022 $479 $152 $48–$470 $149
2023 $533 $166 $54–$529 $160
2024 $889 $173 $55–$556 $164
2025 $686 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $550 40 payments
  2. Novo Nordisk Inc $306 21 payments
  3. AstraZeneca Pharmaceuticals LP $276 12 payments
  4. Pfizer Inc. $247 17 payments
  5. Lilly USA, LLC $183 10 payments
  6. Amgen Inc. $174 5 payments
  7. Novartis Pharmaceuticals Corporation $149 10 payments
  8. Exact Sciences Corporation $119 7 payments
  9. Lundbeck LLC $106 5 payments
  10. UCB, Inc. $101 5 payments
  11. Other $1,000 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,198 186 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $306 21 payments
  2. RYBELSUS $289 20 payments
  3. FARXIGA $214 8 payments
  4. VRAYLAR $210 13 payments
  5. UBRELVY $202 18 payments
  6. MOUNJARO $183 10 payments
  7. EVENITY $161 4 payments
  8. NURTEC ODT $132 10 payments
  9. ENTRESTO $121 8 payments
  10. Cologuard Collection Kit $119 7 payments
  11. Other $2,220 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

2,856

Median for Nurse Practitioner: 389

Drug cost

$110,464

Median for Nurse Practitioner: $21,885

Branded share of claims

16.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 48 $33,215
Januvia Sitagliptin Phosphate Brand 22 $17,335
Rybelsus Semaglutide Brand 14 $15,103
Ozempic Semaglutide Brand 13 $10,374
Myrbetriq Mirabegron Brand 19 $9,195
Levothyroxine Sodium Generic 324 $2,375
Atorvastatin Calcium Generic 213 $1,588
Oxybutynin Chloride Er Oxybutynin Chloride Brand 35 $1,486
Omeprazole Generic 96 $1,405
Lisinopril Generic 160 $1,030

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$44,744

Of which drugs: $2,664

Medicare patients

200

Average age 74

Services billed

1,170

147 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 50%
Diabetes 23%
Atrial fibrillation 18%
Depression 18%
Ischemic heart disease 15%
Chronic kidney disease 15%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 22 22 $1,770

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $103
$103 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $84
$84 48 —
RYBELSUS
  • Novo Nordisk Inc $79
$79 14 —
Ozempic
  • Novo Nordisk Inc $79
$79 13 —
REXULTI
  • Lundbeck LLC $38
  • Otsuka America Pharmaceutical, Inc. $27
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record